Home  >  Products  >  IDH3B (isocitrate dehydrogenase 3 (NAD+) beta ) Blocking Peptide (the N terminal of IDH3B)(100ug)
IDH3B (isocitrate dehydrogenase 3 (NAD+) beta ) Blocking Peptide (the N terminal of IDH3B)(100ug)

IDH3B (isocitrate dehydrogenase 3 (NAD+) beta ) Blocking Peptide (the N terminal of IDH3B)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-IDH3B Antibody (ARP66591_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP66591
Size: 100ug
Weight: 42kDa
Gene: 3420
Format: Lyophilized powder
Target: Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. NAD(+)-dependent isocitrate dehydrogenases catalyze the allosterically regulated rate-limiting step of the tricarboxylic acid cycle. Each isozyme is a heterotetramer that is composed of two alpha subunits, one beta subunit, and one gamma subunit. The protein encoded by this gene is the beta subunit of one isozyme of NAD(+)-dependent isocitrate dehydrogenase.
Alternative names: FLJ11043; H-IDHB; MGC903; RP46
See Full Product Listings >